Indegene Ltd is a digital-first healthcare and technology company that helps biopharmaceutical, emerging biotech, and medical device companies to develop products and get them to market. The company brings together healthcare domain expertise, technology, and an agile operating model to provide diverse solutions for patients and physicians. Based in Bangalore, the company provides consulting in pharmaceutical marketing, clinical trials, pharmacovigilance, medical and regulatory affairs, and health informatics.
Indegene was founded in 1998 by Dr. Rajesh Nair, Manish Gupta, Gaurav Kapoor, Dr. Sanjay Parikh, and Anand Kiran. Over the years, the company has evolved into a comprehensive service provider for the life sciences industry, offering end-to-end solutions across commercial, medical, regulatory, and R&D operations.
The company segment includes Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation, and Others, with key revenue generated from the Omnichannel Activation segment.
Under the umbrella of Enterprise Medical Solutions, the company establishes Centres of Excellence (CoEs) to consolidate large-scale regulatory and medical operations for clients. These multidisciplinary teams work on client engagements, offering services such as medical content writing, regulatory submissions, product labeling, and more. The service also reviews medical communications to ensure compliance with regulatory guidelines and ethical practices, besides, providing pharmacovigilance services, and conducting real-world evidence (RWE) based medical research to support market access and pricing strategies.
Indegene's proprietary Generative AI capabilities provide your teams with the tools, methodologies, and best practices needed to quickly scale from pilot projects to full-scale solutions. Our expertise in Generative AI for life sciences is gaining industry-wide recognition. Indegene has been named a leader in Generative AI by HFS Research, and our AI-powered Content Creation solution has earned the 2024 Silver Stevie® Award for Technology Innovation of the Year in Healthcare.
Indegene's enterprise commercial solutions enable life sciences companies to efficiently scale their engagement strategies for healthcare professionals and patients while leveraging technology and analytics for enhanced personalization. As a result, life sciences companies can transform their commercial operations for a digital-first world.
The company has also developed omnichannel activation solutions which provide life sciences companies with a 'digital-first' approach to optimizing last-mile promotion of biopharmaceutical products and medical devices to healthcare professionals across multiple channels. The company's NEXT HCP Journey Optimization platform plays a vital role in delivering 'Digital Rep Equivalence' by assisting with customer segmentation, channel optimization, and more effective deployment of medical representatives.
As of May 23, 2025, at 03:57 PM, the market capitalization of Indegene Ltd stood at ₹14,402.88 Crore. The company has demonstrated strong financial performance in recent years.
For the fiscal year ended March 2025:
- Sales rose 9.64% to ₹2,839.30 Crore in the year ended March 2025, as against ₹2,589.60 Crore during the previous year ended March 2024.
- Net profit rose 20.79% to ₹406.70 Crore in the year ended March 2025, as against ₹336.70 Crore during the previous year ended March 2024.
For the quarter ended March 2025:
- Sales rose 12.27% to ₹755.60 Crore in the quarter ended March 2025, as against ₹673.00 Crore during the previous quarter ended March 2024.
- Net profit of Indegene rose 24.05% to ₹117.60 Crore in the quarter ended March 2025, as against ₹94.80 Crore during the previous quarter ended March 2024.
Company has delivered good profit growth of 67.9% CAGR over the last 5 years. Company has a good return on equity (ROE) track record: 3 Years ROE 24.3%.
Indegene went public in May 2024 with an initial public offering, raising ₹1,842 Crore (US$220 million). The shares got listed on BSE, NSE on May 13, 2024.
Indegene named leader in ISG's 2025 Life Sciences Digital Services evaluation. The company has received multiple industry recognitions, positioning itself as a market leader in life sciences digital services.
Indegene, a digital-first life sciences commercialization company, recently announced the launch of a new center in London. This aligns with the company's long-term growth strategy in Europe, reiterating its commitment to enable life sciences clients in the region to be future-ready. Indegene's Europe-based clients can now benefit from this center as a strategic hub for consulting and commercialization solutions and modernize their operations with an AI-first approach.
Indegene's most recent deal was a Buyout/LBO with Trilogy Writing & Consulting on March 27, 2024. Indegene successfully integrated its recent acquisition of Trilogy, enhancing its medical writing capabilities and contributing to its comprehensive service offerings.
As a testament to its expertise and market dominance in the life sciences industry, this industry frontrunner has consistently generated over 70% of its total revenue from continuing operations through its top-tier clients since 2020.
Indegene Limited is experiencing a transformative year as it transitions to a publicly listed entity, emphasizing transparency and proactive investor engagement amidst macroeconomic uncertainties and regulatory challenges. The company reported a 4.9% quarter-on-quarter revenue growth in Q4 FY '25, driven by strategic deal wins and a strong cash position, despite a slight decrease in active clients. Its AI-based platform, Cortex, is positioned to enhance compliance in the life sciences sector, addressing client needs amid evolving regulations. While facing challenges with key customers, Indegene remains optimistic about future growth, particularly through recurring revenue streams and strategic acquisitions, all while maintaining a prudent approach to dividends and financial stability.
The company's strategic focus on digital transformation, AI-powered solutions, and comprehensive service offerings positions it well to capitalize on the growing demand for specialized life sciences services in an increasingly digital healthcare landscape.
